...vivo research (see “Recursion to Expand into New Drug Discovery” ). Cytovia, CytoImmune’s CAR deal Cytovia...
...Inc. has acquired worldwide rights to CytoImmune Therapeutics’ EGFR dual-targeting chimeric antigen receptor (CAR) technology. Cytovia...
...cell therapy to treat glioblastoma and other solid tumors. CytoImmune will receive a stake in Cytovia...

...position. He was VP, development sciences at Kymab Group Ltd. NK cell cancer immunotherapy company Cytovia...
...Ltd. American Association for Cancer Research CalciMedica Inc. Celyad S.A. Confo Therapeutics N.V. Praxis Precision Medicines Inc. Affimed N.V. Summit Therapeutics plc RenovaCare Inc. Cytovia...

...mediated anti-inflammatory and anti-viral effects, Karyopharm said. Cytovia seeking NK cell solution NK cell company Cytovia Inc....
...to start clinical testing by year-end and make the therapy available to patients in 2021. Cytovia...

...will target VEGF and the IL-8 family. Immune will fund the bispecific program through its Cytovia...

...Aurora's partners Allergan American Home Products AntiCancer Becton Dickinson Bristol-Myers Ceres Clontech Cystic Fibrosis Foundation Cytovia...

...Aurora's partners Allergan American Home Products AntiCancer Becton Dickinson Bristol-Myers Ceres Clontech Cystic Fibrosis Foundation Cytovia...

...Vick as VP of worldwide business development and licensing, formerly VP of corporate development at Cytovia Inc. WIR...

...Reverse Genomics technology to analyze the mode of action of an apoptosis-inducing compound from Cytovia. Cytovia...
...certain mammalian cell-based assay technologies for use in GPC's in-house and partnered drug discovery programs. Cytovia Inc....

...to analyze the mode of action of an apoptosis-inducing compound from Cytovia (San Diego, Calif.). Cytovia...

...BCHE and MAXM's Cytovia Inc. subsidiary (San Diego, Calif.) will develop Cytovia's CV2105 series of small molecules...